EUVIMEDEUVIMED entdecken
Crossref

L26/P-470 Optimal duration of tacrolimus after conception in women with recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) and elevated Th1/Th2 ratios

S. Ohgi, K. Nakagawa, J. Kwak -Kim, K. Kuroda, A. Moriyama, R. Tsutsumi, H. Motoyama, Y. Kuribayashi, R. Sugiyama

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Ohgi und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question In pregnant women with RIF or RPL and elevated Th1/Th2 ratios, how long should tacrolimus be continued after conception? Summary answer Discontinuation of tacrolimus at 12 weeks’ gestation did not increase the risk of preeclampsia (PE) in women with RIF or RPL and elevated Th1/Th2 ratios. What is known already Reproductive failures, including RIF and RPL, have been associated with immunological imbalance, particularly elevated Th1/Th2 ratios. Tacrolimus has been used to improve reproductive outcomes in women with immune-mediated implantation failure or pregnancy loss. Elevated Th1/Th2 ratios have been implicated as a risk factor for pregnancy-related complications, including preeclampsia (PE). However, the optimal duration of tacrolimus treatment after pregnancy remains undefined, and it is unclear whether continuation beyond the first trimester confers additional risk. Study design, size, duration Serum IFN-γ and IL-4 were measured in the study population, with elevated Th1 and Th1/Th2 defined as ≥ 28.8 and ≥11.8, respectively. Between October 2018 and September 2025, we enrolled 511 consecutive women with elevated Th1/Th2 ratios who received tacrolimus in a two-center retrospective cohort. Women with Th1/Th2 ratios of 11.8–18.9 and ≥19.0 received tacrolimus 2 and 3 mg/day, respectively, starting 1–2 days before embryo transfer (RIF) or at a positive pregnancy test (RPL). Participants/materials, setting, methods Participants (n = 511) were classified by the time of tacrolimus discontinuation: early (< 12 weeks; n = 305), mid (13–27 weeks; n = 69), or late (28 weeks; n = 137). Perinatal outcomes were retrospectively analyzed in each group, including PE, placental abruption, and HELLP syndrome. Gestational diabetes mellitus (GDM), a known adverse effect of tacrolimus, was also assessed. Main results and the role of chance Values are mean ± SD. Maternal age did not differ between the early, mid, and late groups (37.5 ± 4.1, 37.7 ± 4.0, and 38.1 ± 3.8 years, respectively; p = 0.434). Th1/Th2 ratios differed among early, mid, and late groups (13.7 ± 7.2, 11.8 ± 5.6, and 15.4 ± 12.8, respectively; p = 0.020), as did tacrolimus doses (2.1 ± 0.8, 2.2 ± 0.7, and 2.6 ± 0.8 mg/day, respectively; p = 0.0001).The incidence of PE did not differ between the early and mid groups (6.9% [21/305] vs. 5.8% [4/69]; OR 0.83, 95% CI 0.28–2.51; p = 1.00), nor between the early and late groups (6.9% [21/305] vs. 9.5% [13/137]; OR 1.42, 95% CI 0.69–2.92; p = 0.340, Fisher’s exact test). Among PE cases, the majority were hypertensive disorders of pregnancy. HELLP syndrome occurred in two women in the early group, and one in the late group, while placental abruption occurred in one woman in the early group. The prevalence of GDM was comparable across study groups (5.9% [n = 18], 2.9% [n = 2], and 5.8% [n = 8]; p = 0.598). Limitations, reasons for caution Although the prevalence of PE was comparable to the reported Japanese baseline (∼6.7%), the study may have been underpowered to detect small differences between groups. Larger prospective studies are needed to confirm these findings with subgroup analysis. Wider implications of the findings In women with elevated Th1/Th2 ratios who received Tacrolimus treatment, discontinuation after the first trimester was not associated with increased risk of PE or GDM. Identification of subgroups that may benefit from prolonged tacrolimus therapy warrants further investigation. Trial registration number Yes

Zitieren

APA

Ohgi, S., Nakagawa, K., -Kim, J. K., Kuroda, K., Moriyama, A., Tsutsumi, R., Motoyama, H., Kuribayashi, Y., & Sugiyama, R. (2026). L26/P-470 Optimal duration of tacrolimus after conception in women with recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) and elevated Th1/Th2 ratios. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.804

Vancouver

Ohgi S, Nakagawa K, -Kim JK, Kuroda K, Moriyama A, Tsutsumi R, et al. L26/P-470 Optimal duration of tacrolimus after conception in women with recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) and elevated Th1/Th2 ratios. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.804

BibTeX
@article{Ohgi2026,
  author = {Ohgi, S. and Nakagawa, K. and -Kim, J. Kwak and Kuroda, K. and Moriyama, A. and Tsutsumi, R. and Motoyama, H. and Kuribayashi, Y. and Sugiyama, R.},
  title = {L26/P-470 Optimal duration of tacrolimus after conception in women with recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) and elevated Th1/Th2 ratios},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.804}
}
Kostenlos starten →